Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.41 |
| ▸ | BRD4 | O60885 | 9/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419356 | 0.74 | CREBBP (0.59) | CREBBPBRD4EP300TSHR | |
| SCHEMBL29660000 | 0.74 | CREBBP (0.59) | CREBBPBRD4EP300TSHR | |
| SCHEMBL21131358 | 0.73 | NNMT (0.37) | CDC7CREBBPBRD4EP300TSHR | |
| SCHEMBL3663375 | 0.72 | MAOA (0.41) | TSHRMAOAMAOBCDC25B | |
| SCHEMBL31749955 | 0.71 | TSHR (0.60) | CDC7CREBBPBRD4TSHRMKNK1 | |
| SCHEMBL22868112 | 0.70 | ACHE (0.46) | CREBBPBRD4EP300TSHRMAOB | |
| SCHEMBL22774228 | 0.69 | MEN1 (0.47) | CDC7MKNK1MAOAMAOBCDC25B | |
| SCHEMBL20288981 | 0.69 | PBRM1 (0.51) | CREBBPBRD4EP300TSHR | |
| SCHEMBL11724231 | 0.69 | ACHE (0.47) | CREBBPBRD4EP300TSHRMAOB | |
| SCHEMBL4595981 | 0.68 | GSK3B (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | CDC7 4726/4885CREBBP 958/4885BRD4 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.